⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8893888 | 1.00 | — | — | |
| SCHEMBL27339237 | 0.71 | — | — | |
| SCHEMBL8578482 | 0.65 | — | — | |
| SCHEMBL10700060 | 0.64 | — | — | |
| SCHEMBL7161283 | 0.61 | — | — | |
| SCHEMBL7161276 | 0.61 | — | — | |
| SCHEMBL8676002 | 0.60 | — | — | |
| SCHEMBL29603678 | 0.60 | — | — | |
| SCHEMBL8184754 | 0.60 | — | — | |
| SCHEMBL4599052 | 0.59 | NFKB1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579696-B1 | Comprising diaminobutyric acid having a gamma amino group and amino acid selected from cysteine, alanine and lysine; use in prevention and treatment of sepsis | PROMEGA CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-5998381-A | PROVIDING SUBJECT WITH BACTERIAL DISEASE WITH FIMBRIAE BINDING COMPOUND COMPRISING ANOMERIC MANNOSE, AN AROMATIC OR HETEROAROMATIC RING ATTACHED TO MANNOSE BY GLYCOSIDIC LINKAGE AND FUNCTIONAL GROUP PROVIDING MODIFICATION SITE | OPHIDIAN PHARMACEUTICALS, INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0840619-A1 | PREVENTION AND TREATMENT OF SEPSIS | OPHIDIAN PHARMACEUTICALS, INC. (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1996040251-A1 | PREVENTION AND TREATMENT OF SEPSIS | OPHIDIAN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5162502-A | Immunotoxins | SANOFI (FR) | 1992-11-10 | — | — | US | disclosed |
| EP-0220899-B1 | BIFUNCTIONAL LINKER | Immunomedics, Inc. (US) | 1992-03-11 | — | — | EP | disclosed |
| US-5037960-A | Antitumor agents | SANOFI (FR) | 1991-08-06 | — | — | US | disclosed |
| US-4954638-A | ANTIALLERGENS, ANTIINFLAMMATORY | MERCK FROSST CANADA, INC. (CA) | 1990-09-04 | — | — | US | disclosed |
| US-4767621-A | MONEUSIN, NIGERICIN, GRISORIXIN AND LASALOCID; A CHAIN OF RICIN; BONDED TO ANTIBODY | SANOFI (FR) | 1988-08-30 | — | — | US | disclosed |
| US-4767745-A | 1,5-DIFLUORO-2,4-DINITRO BENZENE AND 6-N-MALEIMIDOHEXANOIC ACID CHLORIDE AS COUPLING AGENTS; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1988-08-30 | — | — | US | disclosed |
| EP-0256907-A1 | Protein synthesis inhibitor, process for its isolation, use, and pharmaceutial compositions containing it | SANOFI S.A. (FR) | 1988-02-24 | — | — | EP | disclosed |
| US-4680338-A | Bifunctional linker | IMMUNOMEDICS, INC. (US) | 1987-07-14 | — | — | US | disclosed |
| US-4614650-A | RICIN AND DERIVATIVES | SANOFI (FR) | 1986-09-30 | — | — | US | disclosed |
| EP-0179959-A1 | Conjugates of leukotrienes with proteins | MERCK FROSST CANADA INC. (CA) | 1986-05-07 | — | — | EP | disclosed |
| US-4582703-A | Cytotoxic medicament formed from the association of at least one immunotoxin and chloroquin | SANOFI (FR) | 1986-04-15 | — | — | US | disclosed |
| US-4340535-A | CANCER CELLS | C M INDUSTRIES (FR) | 1982-07-20 | — | — | US | disclosed |